Dolutegravir Sodium

多替拉韦钠

Report date: 2026/02/06 20:01:23
NME

Base Information

Drug NameDolutegravir Sodium
Drug Alias Namedolutegravirum多特雷韦Dolutegravir杜鲁特韦德罗特韦 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsParturitionHepatitisHepatic Insufficiency +[7] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2013/08/12
Country/TerritoryBelgiumCanadaBotswana +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of LiegeUniversity of StellenboschHumanis Saglık Anonim Sirketi +[17] 
Inactive CompaniesCampus Pharma AbNational Cancer InstituteChulalongkorn University +[4] 
Active IndicationsParturitionHIV InfectionsTuberculosis
Inactive IndicationsHepatitisHepatic InsufficiencyHerpesviridae Infections +[4] 

Other Information

ATC CodeJ05AJ03
Related LinksWikipediaDrugBankKEGG